AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31038476 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model based on FAT HR, resting heart rate, and FAT
Number of subjects: 200
Study 27748623 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amikacin for inhalation (LAI) 590 mg once daily for 84 days
Number of subjects: 89
Study 27748623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 25648577 — intervention group
Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire
Number of subjects: 3400
Study 25648577 — intervention group
Group type: EXPERIMENTAL
Intervention: European QOL 5D Visual Analog Scale
Number of subjects: 3400
Study 25648577 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire‐9
Number of subjects: 3400
Study 23279373 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (50 mg/day, increased to 100 mg/day if HbA1c ≥6.5% at 16 weeks)
Number of subjects: 130
Study 23279373 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone (15 mg/day, increased to 30 mg/day if HbA1c ≥6.5% at 16 weeks)
Number of subjects: 130
Study 23279373 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 130
Study 23279373 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 130
Study 18728056 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-endurance exercise (cycled and jogged for 17 of 24 h)
Number of subjects: 9
Study 18728056 — intervention group
Group type: COMPARATOR
Intervention: Control rest period
Number of subjects: 9
Study 18728056 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-endurance exercise
Number of subjects: 9
Study 19786145 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypeptide vaccine (EP-1043)
Number of subjects: 84
Study 16924021 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine-induced vasodilation
Number of subjects: 14
Study 16924021 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside-induced vasodilation
Number of subjects: 14
Study 15297403 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC = 5.5 mg/ml x min day 1) and gemcitabine (1000 mg/m(2) days 1 and 8 every 21 days x 3) followed by paclitaxel (225 mg/m(2) every 21 days x 3)
Number of subjects: 178
Study 15297403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m(2) day 1), vinorelbine (25 mg/m(2) days 1 and 8 every 21 days x 3) followed by docetaxel (75-100 mg/m(2) every 21 days x 3)
Number of subjects: 178
Study 11707557 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-calorie diets (VLCDs) with active follow-up treatment including behavior therapy, nutritional education, and exercise
Number of subjects: 0
Study 11707557 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-calorie diets (VLCDs)
Number of subjects: 0
Study 11707557 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie diets (400 to 800 kcal)
Number of subjects: 0
Study 9688247 — intervention group
Group type: EXPERIMENTAL
Intervention: Local estrogen, physiotherapy, and electrostimulation with close follow-up
Number of subjects: 90
Study 9688247 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment
Number of subjects: 90
Study 7867399 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplement (100 micrograms/d for 6-8 weeks)
Number of subjects: 52
Study 7867399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 7867399 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplement
Number of subjects: 52
Study 2802852 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinfusion of shed mediastinal blood using hard-shell cardiotomy reservoir for up to 18 hours postoperatively
Number of subjects: 100
Study 2802852 — intervention group
Group type: COMPARATOR
Intervention: Conventional mediastinal drainage
Number of subjects: 100
Study 2802852 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinfusion of shed mediastinal blood
Number of subjects: 100
Study 1030548 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Cytoxan)
Number of subjects: 0
Study 1030548 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 0
Study 1030548 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent chemotherapies
Number of subjects: 0
Study 1030548 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial and crossover chemotherapy
Number of subjects: 0
Study 1030548 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study 31742630 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Number of subjects: 474
Study 31742630 — intervention group
Group type: COMPARATOR
Intervention: Delayed umbilical cord clamping
Number of subjects: 474
Study 31742630 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking (for infants born at 23 to 27 weeks' gestation)
Number of subjects: 474
Study 31742630 — intervention group
Group type: COMPARATOR
Intervention: Delayed umbilical cord clamping (for infants born at 23 to 27 weeks' gestation)
Number of subjects: 474
Study 28331925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 46
Study 28331925 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 46
Study 26135280 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention using a goal-oriented set of case management and counseling techniques to promote self-management.
Number of subjects: 0
Study 23737390 — intervention group
Group type: EXPERIMENTAL
Intervention: Endeavor Zotarolimus‐eluting stent (E‐ZES)
Number of subjects: 601
Study 23737390 — intervention group
Group type: COMPARATOR
Intervention: Other drug-eluting stents (DES)
Number of subjects: 601
Study 21393114 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education guided by 'Dietary Guidelines for Chinese Residents' for one year
Number of subjects: 272
Study 21393114 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 272
Study 19372620 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 130
Study 19372620 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 130
Study 19372620 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg or 40 mg
Number of subjects: 130
Study 16489942 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque index
Number of subjects: 12
Study 16489942 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque weight
Number of subjects: 12
Study 16489942 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush brushing for 2 min
Number of subjects: 12
Study 14642699 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 150
Study 14642699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 10888536 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cups of black tea per day for 4 weeks
Number of subjects: 10
Study 10888536 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study 8869095 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical vancomycin in addition to ceftazidime or piperacillin-tobramycin
Number of subjects: 897
Study 8869095 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime or piperacillin-tobramycin without vancomycin
Number of subjects: 897
Study 1824048 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoamine oxidase inhibitors (MAOI)
Number of subjects: 130
Study 1824048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 6785807 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 0
Study 31453915 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation with continuous theta burst stimulation (cTBS)
Number of subjects: 13
Study 31453915 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 13
Study 31111250 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading training (RT) for 6 weeks using sequentially presented text (RSVP)
Number of subjects: 37
Study 31111250 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading training (RT) for 6 weeks
Number of subjects: 37
Study 31111250 — intervention group
Group type: COMPARATOR
Intervention: Placebo training (crossword puzzles)
Number of subjects: 37
Study 27763785 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy group (AG) with petitgrain essential oil
Number of subjects: 42
Study 27763785 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with neutral oil (almond)
Number of subjects: 42
Study 27763785 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy group (AG) and Control group (CG)
Number of subjects: 42
Study 25888525 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (three monthly treatments for one year, three consecutive days of supervised drug intake)
Number of subjects: 0
Study 25888525 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo (three monthly treatments for one year, three consecutive days of supervised drug intake)
Number of subjects: 0
Study 25888525 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 0
Study 25117425 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (180 μg/week) + Ribavirin (1000/1200 mg/day)
Number of subjects: 212
Study 25117425 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa-2b (1.5 μg/kg/week) + Ribavirin (1000/1200 mg/day)
Number of subjects: 212
Study 25117425 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a + Ribavirin
Number of subjects: 212
Study 25117425 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa-2b + Ribavirin
Number of subjects: 212
Study 22378331 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet preload (0.35 L fruit juice)
Number of subjects: 15
Study 22378331 — intervention group
Group type: EXPERIMENTAL
Intervention: Savory preload (0.35 L tomato juice)
Number of subjects: 15
Study 25885239 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tramadol (1 mg/kg) (n=20)
Number of subjects: 40
Study 25885239 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal tramadol (1.5‐2 mg/kg, maximum 100 mg) (n=20)
Number of subjects: 40
Study 17671253 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate (17P) 250 mg weekly intramuscular injections
Number of subjects: 655
Study 17671253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 655
Study 17671253 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate (17P)
Number of subjects: 655
Study 16225528 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin 7.5 mg once daily
Number of subjects: 27
Study 16225528 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin 15 mg once daily
Number of subjects: 27
Study 16225528 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicyclomine 20 mg four times daily
Number of subjects: 27
Study 16225528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 12385694 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g
Number of subjects: 110
Study 12385694 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem 1.5 g
Number of subjects: 110
Study 12385694 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone plus metronidazole
Number of subjects: 110
Study 12385694 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g and 1.5 g
Number of subjects: 110
Study 10233270 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbinafine for 1 week
Number of subjects: 35
Study 10233270 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbinafine for 2 weeks
Number of subjects: 35
Study 10233270 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbinafine for an additional 4 weeks (for non-responders)
Number of subjects: 35
Study 10233270 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbinafine for an additional 4 weeks (for Microsporum infections)
Number of subjects: 35
Study 10233270 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 35
Study 7479198 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbate 4.5 g/day
Number of subjects: 44
Study 7479198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 2757905 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 8
Study 2757905 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (fasting state)
Number of subjects: 8
Study 4901340 — intervention group
Group type: EXPERIMENTAL
Intervention: Bordetella pertussis vaccine
Number of subjects: 0
Study 4901340 — intervention group
Group type: COMPARATOR
Intervention: Intensive chemotherapy
Number of subjects: 0
Study 30930140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron
Number of subjects: 150
Study 30930140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 28985434 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin administration (24 IU)
Number of subjects: 24
Study 28985434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26573509 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0
Study 26573509 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0
Study 23733149 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trial consideration by oncologists
Number of subjects: 293
Study 23733149 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trial offers
Number of subjects: 293
Study 23733149 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial acceptance
Number of subjects: 293
Study 23733149 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial refusal
Number of subjects: 293
Study 23733149 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligibility factors
Number of subjects: 293
Study 22058105 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case manager intervention and automated VTE-risk-assessment tool
Number of subjects: 0
Study 18423985 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1077
Study 22097102 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to a steady beat of 66 beats per minute
Number of subjects: 36
Study 22097102 — intervention group
Group type: COMPARATOR
Intervention: Sitting in silence (Control)
Number of subjects: 36
Study 16005154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (INF)
Number of subjects: 24
Study 16005154 — intervention group
Group type: COMPARATOR
Intervention: Oral morphine (OM)
Number of subjects: 24
Study 15384292 — intervention group
Group type: EXPERIMENTAL
Intervention: IAN block plus labial infiltration (1.8 mL of 2% lidocaine with 1:100,000 epinephrine)
Number of subjects: 40
Study 15384292 — intervention group
Group type: COMPARATOR
Intervention: IAN block alone (3.6 mL of 2% lidocaine with 1:100,000 epinephrine)
Number of subjects: 40
Study 9648960 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 200 microg (2x100 microg) via metered dose inhaler with a spacer
Number of subjects: 0
Study 9648960 — intervention group
Group type: COMPARATOR
Intervention: Sham challenge with normal saline
Number of subjects: 0
Study 9648960 — intervention group
Group type: COMPARATOR
Intervention: Histamine/methacholine challenge
Number of subjects: 0
Study 8024992 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 300 mg twice daily for 4 weeks
Number of subjects: 0
Study 8024992 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily for 4 weeks
Number of subjects: 0
Study 8024992 — intervention group
Group type: COMPARATOR
Intervention: Adverse events for both etodolac and naproxen
Number of subjects: 0
Study 3058613 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) during exercise
Number of subjects: 11
Study 3058613 — intervention group
Group type: COMPARATOR
Intervention: Placebo during exercise
Number of subjects: 11
Study 11376312 — intervention group
Group type: EXPERIMENTAL
Intervention: Slotted tube stent
Number of subjects: 82
Study 11376312 — intervention group
Group type: COMPARATOR
Intervention: Self-expanding stent
Number of subjects: 82
Study 30531234 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine 2.16 mg/d
Number of subjects: 603
Study 30531234 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine 2.88 mg/d
Number of subjects: 603
Study 30531234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 603
Study 29342248 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus fulvestrant
Number of subjects: 1187
Study 29342248 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 1187
Study 29342248 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 1187
Study 29342248 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus letrozole
Number of subjects: 1187
Study 27677387 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI risk score
Number of subjects: 2854
Study 27677387 — intervention group
Group type: EXPERIMENTAL
Intervention: Constructed predictive model including LVEF and eGFR
Number of subjects: 2854
Study 25063959 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy (MBCT)
Number of subjects: 46
Study 25063959 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 46
Study 22282478 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus/mycophenolate mofetil
Number of subjects: 82
Study 22282478 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus/sirolimus
Number of subjects: 82
Study 20104189 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg alone or in association with 12.5 or 25 mg hydrochlorothiazide (HCTZ)
Number of subjects: 30
Study 20104189 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 20 mg in association with 25 mg HCTZ
Number of subjects: 30
Study 20104189 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg in association with 25 mg HCTZ
Number of subjects: 30
Study 20104189 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg in association with 25 mg HCTZ
Number of subjects: 30
Study 20104189 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan +/‐ HCTZ
Number of subjects: 30
Study 20104189 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan/HCTZ
Number of subjects: 30
Study 20104189 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/HCTZ
Number of subjects: 30
Study 20104189 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan/HCTZ
Number of subjects: 30
Study 20104189 — intervention group
Group type: COMPARATOR
Intervention: Ang II
Number of subjects: 30
Study 17603140 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based cardiovascular-fitness training program (10 weeks, 3 times/week, 1 hr/session at 60‐80% peak heart rate)
Number of subjects: 30
Study 17603140 — intervention group
Group type: COMPARATOR
Intervention: Control group (CN)
Number of subjects: 30
Study 14961168 — intervention group
Group type: EXPERIMENTAL
Intervention: Inogatran (low molecular weight direct thrombin inhibitor)
Number of subjects: 320
Study 14961168 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 320
Study 12458652 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 0
Study 12458652 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 0
Study 12458652 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 0
Study 12458652 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 12458652 — intervention group
Group type: COMPARATOR
Intervention: Candesartan vs Valsartan
Number of subjects: 0
Study 9657564 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy
Number of subjects: 25
Study 7907731 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic peptide corresponding to amino acids 31-49 of A-gliadin
Number of subjects: 4
Study 7907731 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic peptide corresponding to amino acids 202-220 of A-gliadin
Number of subjects: 4
Study 7907731 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal peptide, residues 3-21 of A-gliadin
Number of subjects: 4
Study 7907731 — intervention group
Group type: COMPARATOR
Intervention: Intraduodenal infusion of 1 g of gliadin
Number of subjects: 4
Study 2532579 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salt diet
Number of subjects: 6
Study 2532579 — intervention group
Group type: COMPARATOR
Intervention: Normal sodium diet
Number of subjects: 6
Study 4566100 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 4566100 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylobarbitone sodium
Number of subjects: 0
Study 4566100 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide
Number of subjects: 0
Study 4566100 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluoperazine
Number of subjects: 0
Study 4566100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30343857 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia testing intervention (multifaceted, clinic-based including computerized reminders, education package, payments for testing, feedback on testing rates)
Number of subjects: 179355
Study 30343857 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 179355
Study 27892761 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition (GSP)
Number of subjects: 80
Study 27892761 — intervention group
Group type: COMPARATOR
Intervention: Stress condition (non-GSP)
Number of subjects: 80
Study 27892761 — intervention group
Group type: EXPERIMENTAL
Intervention: Control condition (GSP)
Number of subjects: 80
Study 27892761 — intervention group
Group type: COMPARATOR
Intervention: Control condition (non-GSP)
Number of subjects: 80
Study 26488613 — intervention group
Group type: EXPERIMENTAL
Intervention: Robuvit® (Quercus robur wood extract)
Number of subjects: 61
Study 26488613 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 61